Powder: -20°C for 3 years | In solvent: -80°C for 1 year
P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 449.00 | |
10 mg | In stock | $ 659.00 | |
25 mg | In stock | $ 987.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 1,880.00 | |
500 mg | In stock | $ 3,780.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 513.00 |
Description | P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage. |
Targets&IC50 | Syk kinase:1-2 nM |
In vitro | In human whole blood, P505-15 potently inhibited B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM) [1]. P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL [2]. PRT318 and P505-15 effectively antagonize CLL cell survival after BCR triggering and in nurse-like cell-co-cultures. Moreover, they inhibit BCR-dependent secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell migration toward the tissue homing chemokines CXCL12, CXCL13, and beneath stromal cells. PRT318 and P505-15 furthermore inhibit Syk and extracellular signal-regulated kinase phosphorylation after BCR triggering [3]. |
In vivo | Similar levels of ex vivo inhibition were measured after dosing in mice (Syk signaling IC50 0.32 μM). Oral administration of P505-15 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis [1]. Oral dosing in mice prevented BCR-mediated splenomegaly and significantly inhibited NHL tumor growth in a xenograft model. In addition, combination treatment of primary CLL cells with P505-15 plus fludarabine produced synergistic enhancement of activity at nanomolar concentrations [2]. |
Synonyms | PRT 062607 Acetate, P505 15 Acetate, PRT-062607 Acetate, PRT062607 Acetate, P50515 Acetate |
Molecular Weight | 453.5 |
Formula | C21H27N9O3 |
CAS No. | 1370261-98-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (22.05 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
P505-15 Acetate 1370261-98-5 Proteases/Proteasome Tyrosinase PRT 062607 Acetate P 50515 Acetate P-50515 Acetate P505 15 Acetate PRT-062607 Acetate PRT062607 Acetate P50515 Acetate inhibitor inhibit